Aeterna Zentaris appoints Michael Teifel, Ph.D. as Senior
– Over 20 years of industry experience translating research into clinical development in a wide range of therapeutic areas endocrinology and oncology
CHARLESTON, SC, May 3, 2021 (GLOBE NEWSWIRE) – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (âAeternaâ or the âCompanyâ), a specialty biopharmaceutical company marketing a diverse portfolio of pharmaceutical and diagnostic products, today announced the appointment of Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Scientific Director.
Dr. Teifel is an industry leader with a career spanning over 20 years in a variety of therapeutic areas including endocrinology and oncology. He has extensive experience in translating research into clinical development. During his career, he has acquired particular expertise in the design and implementation of non-clinical development programs for small molecule drugs, peptides, targeted therapies and biologics, as well as in non-clinical evaluation. continuous clinic of drug candidates for global registration.
âWe are very happy to welcome back Dr Teifel to Aeterna Zentaris,â commented Dr Klaus Paulini, CEO of Aeterna. “He has extensive knowledge and expertise, including having played a critical role for the company in the development and approval of macimorelin, which is now the first and only oral test approved by the US FDA and the European Commission. indicated for the diagnosis of growth hormone deficiency in adults. . We believe he is a valuable asset to the team as we seek to advance our diverse portfolio of pharmaceuticals and diagnostics. ”
Dr Teifel joins Aeterna Zentaris after having held various positions in industry with increasing responsibilities in pharmacology, pharmacokinetics, toxicology and translational sciences. He began his career in industry at Roche Diagnostics in the area of âânon-viral gene therapy / delivery systems. In 1999, Dr Teifel joined the biotechnology start-up, Munich Biotech in Martinsried, Germany as a co-founder. As head of pharmacology and toxicology, he was responsible for the evaluation and non-clinical development of novel vascular targeting technology for the development of anti-tumor diagnostics and therapies. In 2004, Dr Teifel started his first mandate at Aeterna Zentaris where he held several positions in the field of preclinical development and translational research. In his capacity, he was, among other things, responsible for the preparation of the non-clinical registration dossier for macimorelin in the United States and in the EU in the indication AGHD. In 2019, Dr Teifel left Aeterna Zentaris to pursue her career in non-clinical research and development at Cleara Biotech in Utrecht, The Netherlands. As head of translational sciences at Cleara Biotech, he was responsible for translating research on anti-senescent drugs in preclinical development in age-related diseases and advanced stage cancers.
Dr Teifel holds a degree in biology and his doctorate. from the Technical University of Darmstadt, Germany.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company that develops and markets a diverse portfolio of pharmaceutical and diagnostic products focused on areas where medical needs are not being met. The company’s flagship product, macimorelin, is the first and only oral test approved by the US FDA and the European Commission, indicated for the diagnosis of adult growth hormone deficiency (AGHD). The company is building on the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.
Aeterna Zentaris is dedicated to the development of therapeutic actives and has recently taken steps to establish a growing pipeline to address unmet medical needs in a number of indications, including Neuromyelitis Optic Spectrum Disorder (NMOSD), primary hypoparathyroidism and neurodegenerative diseases. In addition, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2, the virus responsible for COVID-19.
For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.
This press release contains statements that may constitute forward-looking statements within the meaning of United States and Canadian securities laws and regulations and such statements are made in accordance with the safe harbor provision of the United States Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible” and similar expressions . These statements, based on management’s current expectations, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking statements in this press release include, but are not limited to, those relating to: Aeterna’s expectations with respect to the P02 study (including the possibility of starting in the second quarter of 2021, of registering subjects in the United States or elsewhere in Study P02, and the expectation that Study P02 is appropriate to support a claim (regulatory approval) for potential stand-alone trials with macimorelin); Aeterna’s expectation that upon receipt of price and reimbursement approvals, macimorelin will be marketed in Europe and the UK; the objectives and details of potential preclinical and clinical studies involving the potential use of macimorelin to treat an undisclosed neurodegenerative disease conducted by the University of Queensland; the potential of the coronavirus vaccine platform technology licensed from Julius-Maximilians-University (and any candidate vaccine using this technology) to be effective as a vaccine against COVID-19 (SARS-CoV-2 ) or any other coronavirus disease or to provide an alternative to other approved COVID-19 vaccines; the ability to obtain approval to begin any clinical trial or schedule for the development of any potential vaccine and the characteristics of any potential vaccine; plans for DC-PTH fusion polypeptides licensed from the University of Sheffield, plans for AIM biologics licensed from Julius-Maximilians University and the processing potential of NMOSD; and Aeterna’s intentions with respect to growth opportunities and its business orientation, including with respect to its cash position and development pipeline (including the ability to accelerate its development pipeline).
Forward-looking statements involve known and unknown risks and uncertainties, as well as other factors that may cause actual results, performance or achievements set forth herein to be materially different from any future results, performance or achievements expressed or implied by forward-looking information. These risks and uncertainties include, among others, our confidence in the success of the pediatric clinical trial in the European Union and the United States for Macrilen â¢ (macimorelin); the start of the P02 study may be delayed or we may not obtain regulatory approval to initiate this study, we may not be able to recruit the expected number of subjects into the P02 study and the outcome of the P02 study may not support obtaining regulatory approval in CGHD, we may be delayed or not successful in obtaining price and reimbursement approvals in Europe and the UK to market macimorelin; the coronavirus vaccine platform technology (and any vaccine candidate using this technology) licensed from Julius-Maximilians-University has never been tested in humans and therefore other preclinical or clinical studies of this technology and any vaccine developed using this technology may not be effective as a vaccine against COVID-19 (SARS-CoV-2) or any other coronavirus disease; that the timeframe for vaccine development may be longer than expected; whereas this technology or these vaccines may not be suitable for oral use, may not have the same characteristics as vaccines previously approved using the carrier strain of Salmonella Typhi Ty21a; the results of ongoing or planned preclinical studies with macimorelin by the University of Queensland or for our other products in development may not be successful or may not support the advancement of the product into human clinical trials; our ability to raise capital and secure financing to continue our currently planned activities; our now heavy reliance on the success of Macrilen â¢ (macimorelin) and associated license agreements and the continued availability of funds and resources to successfully commercialize the product, including our heavy reliance on the success of the agreement license with Novo Nordisk; global instability due to the global COVID-19 pandemic and its unknown potential effect on our planned operations; our ability to enter into and maintain licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies. Investors should consult our quarterly and annual filings with the Canadian and United States securities commissions for additional information on risks and uncertainties, including the risks described in our Annual Report on Form 40-F and in the Annual Information Form, under the heading âRisk Factorsâ. In view of the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update these factors or to publicly announce any revision of any of the forward-looking statements contained herein to reflect future results, events or developments, unless a governmental authority or applicable law requires it. required.
No securities regulatory authority has approved or disapproved of the contents of this press release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this release.
T (United States): +1 (833) 475-8247
E: [email protected]